Welcome to the international HTA database

Showing [24094 Records] Selected Records [0 Hits] [Clear]

Year	Source	Title
2005	Alberta Heritage Foundation for Medical Research (AHFMR)	A guide to health technology assessment in the Palliser health region
2016	Health Information and Quality Authority (HIQA)	A guide to health technology assessment at HIQA
1996	Canadian Coordinating Office for Health Technology Assessment (CCOHTA)	A guidance document for the costing process (version 1.0) - guidelines
2022	NIHR Public Health Research (PHR) programme	A group-based exercise and behavioural maintenance intervention for adults over 65 years with mobility limitations: the REACT RCT
2025	NIHR Health Technology Assessment programme	A group psychological intervention for postnatal depression in British mothers of South Asian origin – the ROSHNI-2 RCT
2019	NIHR Health Technology Assessment programme	A group memory rehabilitation programme for people with traumatic brain injuries: the ReMemBrIn RCT
2011	Agencia de Evaluacion de Tecnologias Sanitarias (AETS)	A framework for science advice on health: principles and guidelines
2011	Agency for Healthcare Research and Quality (AHRQ)	A framework for "best evidence" approaches in systematic reviews
2014	NIHR Health Services and Delivery Research programme	A formative evaluation of Collaboration for Leadership in Applied Health Research and Care (CLAHRC): institutional entrepreneurship for service innovation
2015	NIHR Health Technology Assessment programme	A feasibility study to inform the design of a randomised controlled trial to identify the most clinically effective and cost-effective length of Anticoagulation with Low-molecular-weight heparin In the treatment of Cancer-Associated Thrombosis (ALICAT)
2015	NIHR Health Technology Assessment programme	A feasibility randomised controlled trial of a motivational interviewing-based intervention for weight loss maintenance in adults
2009	NIHR Health Technology Assessment programme	A double-blind randomised placebo controlled trial of topical intranasal corticosteroids in 4- to11-year-old children with persistent bilateral otitis media with effusion in primary care
2014	Belgian Health Care Knowledge Centre (KCE)	A decision aid for an informed choice when patient asks for PSA screening
2014	NIHR Health Services and Delivery Research programme	A cross-sectional prevalence survey of psychotropic medication prescribing patterns in prisons in England
1997	NIHR Health Technology Assessment programme	A critical review of the role of neonatal hearing screening in the detection of congenital hearing impairment
2007	Agency for Healthcare Research and Quality (AHRQ)	A critical analysis of care coordination strategies for children with special health care needs
1998	NIHR Health Technology Assessment programme	A cost-utility analysis of interferon beta for multiple sclerosis
2019	Technology Assessment at SickKids (TASK)	A cost-utility analysis of biosimilar infliximab compared to reference infliximab in adult switch patients with Crohn’s disease: a Canadian analysis
2016	NIHR Health Technology Assessment programme	A cost-effectiveness modelling study of strategies to reduce risk of infection following primary hip replacement based on a systematic review
2015	Technology Assessment at SickKids (TASK)	A cost-effectiveness analysis of maternal genotyping to guide treatment for postpartum pain and avert infant adverse events
2019	NIHR Health Technology Assessment programme	A contingency management intervention to reduce cannabis use and time to relapse in early psychosis: the CIRCLE RCT
1997	British Columbia Office of Health Technology Assessment (BCOHTA)	A comprehensive framework: evaluating programmes to prevent hip fractures in senior women
2008	NIHR Health Technology Assessment programme	A comparison of the effectiveness and cost-effectiveness of interventions for reducing the lifetime fracture risk in children with juvenile idiopathic arthritis - a systematic review with economic modelling
2006	NIHR Health Technology Assessment programme	A comparison of the cost-effectiveness of five strategies for the prevention of non-steroidal anti-inflammatory drug-induced gastrointestinal toxicity: a systematic review with economic modelling
2003	Agency for Healthcare Research and Quality (AHRQ)	A comparison of the cost-effectiveness of fecal occult blood tests with different test characteristics in the context of annual screening in the Medicare population
2021	NIHR Health Technology Assessment programme	A comparison of general anaesthesia versus awake-regional anaesthesia in infancy: an international, multicentre, randomised controlled equivalence trial; the GAS study
2010	Health Services Assessment Collaboration (HSAC)	A comparison of gene expression profiling tests for breast cancer
2007	NIHR Health Technology Assessment programme	A comparison and discussion of the methods, findings, adaptability and decisions resulting from two reviews of vision screening in children undertaken in the UK and Germany
2002	NIHR Health Technology Assessment programme	A comparative study of hypertonic saline, daily and alternate-day rhDNase in children with cystic fibrosis
2013	Belgian Health Care Knowledge Centre (KCE)	A comparative analysis of hospital care payments in five countries
2017	NIHR Health Technology Assessment programme	A cluster randomised trial, cost-effectiveness analysis and psychosocial evaluation of insulin pump therapy compared with multiple injections during flexible intensive insulin therapy for type 1 diabetes: the REPOSE Trial
2017	NIHR Health Technology Assessment programme	A cluster randomised trial, cost-effectiveness analysis and psychosocial evaluation of insulin pump therapy compared with multiple injections during flexible intensive insulin therapy for type 1 diabetes: the REPOSE Trial
2016	NIHR Health Technology Assessment programme	A cluster randomised trial of strategies to increase cervical screening uptake at first invitation (STRATEGIC)
2013	NIHR Health Technology Assessment programme	A cluster randomised controlled trial to determine the clinical effectiveness and cost-effectiveness of classroom-based cognitive-behavioural therapy (CBT) in reducing symptoms of depression in high-risk adolescents
2013	NIHR Health Technology Assessment programme	A cluster randomised controlled trial of a manualised cognitive behavioural anger management intervention delivered by supervised lay therapists to people with intellectual disabilities
2015	NIHR Public Health Research (PHR) programme	A cluster randomised controlled trial comparing the effectiveness and cost-effectiveness of a school-based cognitive behavioural therapy programme (FRIENDS) in the reduction of anxiety and improvement in mood in children aged 9/10 years
2013	NIHR Health Technology Assessment programme	A cluster randomised controlled trial and economic evaluation of a structured training programme for caregivers of inpatients after stroke: the TRACS trial
2024	NIHR Health Technology Assessment programme	A cloud-based medical device for predicting cardiac risk in suspected coronary artery disease: a rapid review and conceptual economic model
2013	Health Council of the Netherlands Gezondheidsraad (GR)	A closer look at Lyme disease
2006	Canadian Agency for Drugs and Technologies in Health (CADTH)	A clinical systematic review of BRCA1 and BRCA2 genetic testing for breast and ovarian cancers
2004	Canadian Coordinating Office for Health Technology Assessment (CCOHTA)	A clinical and economic review of telephone triage services and survey of Canadian call centre programs
2003	Canadian Coordinating Office for Health Technology Assessment (CCOHTA)	A clinical and economic review of stroke rehabilitation services
1998	Canadian Coordinating Office for Health Technology Assessment (CCOHTA)	A clinical and economic review of HMG-CoA reductase inhibitors in coronary heart disease - summary
2003	Canadian Coordinating Office for Health Technology Assessment (CCOHTA)	A clinical and economic review of exercise-based cardiac rehabilitation programs for coronary artery disease
1997	Canadian Coordinating Office for Health Technology Assessment (CCOHTA)	A clinical and economic evaluation of selective serotonin reuptake inhibitors in major depression
2014	NIHR Health Technology Assessment programme	A clinical and economic evaluation of Control of Hyperglycaemia in Paediatric intensive care: the CHiP randomised controlled trial
2019	NIHR Health Technology Assessment programme	A behaviour change package to prevent hand dermatitis in nurses working in health care: the SCIN cluster RCT
2011	NIHR Health Technology Assessment programme	A 1-year follow-on study from a randomised, head-to-head, multicentre, open-label study of two pandemic influenza vaccines in children
2010	The Regional Health Technology Assessment Centre (HTA-centrum)	90Yttrium radioembolisation for hepatocellular carcinoma and colorectal liver metastases
2003	NIHR Horizon Scanning Centre (NIHR HSC)	90Y-muHMFG1 for ovarian cancer - horizon scanning review
2014	Institute for Clinical Evaluative Sciences (ICES)	900,000 days in hospital: The annual impact of smoking, alcohol, diet and physical activity on hospital use in Ontario
2008	Belgian Health Care Knowledge Centre (KCE)	64-slice computed tomography imaging of coronary arteries in patients suspected for coronary artery disease
2010	Medical Advisory Secretariat (MAS)	64-slice computed tomographic angiography for the diagnosis of intermediate risk coronary artery disease
2012	Technology Assessment Unit of the McGill University Health Centre (MUHC)	532 nm KTP laser for vocal fold surgery
2014	Health Council of the Netherlands Gezondheidsraad (GR)	5-Nitroacenaphthene
2001	University HealthSystem Consortium (UHC)	5-HT3 antagonists update
2004	University HealthSystem Consortium (UHC)	5-HT3 antagonist update (2004)
2002	University HealthSystem Consortium (UHC)	5-HT1 agonists for migraine - update
1996	Wessex Institute for Health Research and Development (WIHRD)	5-fluorouracil (5-FU) as adjuvant chemotherapy in Duke's stage C colorectal cancer
2016	HAYES, Inc.	5-aminolevulinic acid photodynamic therapy versus carbon dioxide laser ablation for the treatment of condylomata acuminata
2020	Ontario Health	5-Aminolevulinic Acid Hydrochloride (5 ALA)–Guided Surgical Resection of High-Grade Gliomas: A Health Technology Assessment
2021	Malaysian Health Technology Assessment (MaHTAS)	5-aminolevulinic acid (5-ALA) for brain tumour surgical procedure
2013	All Wales Therapeutics and Toxicology Centre (AWTTC), secretariat of the All Wales Medicines Strategy Group (AWMSG)	5-aminolaevulinic acid (Ameluz®)
2004	German Agency for Health Technology Assessment at the German Institute for Medical Documentation and Information (DAHTA DIMDI)	4th Symposium Health Technology Assessment - Evaluation of medical procedures, 2003, November 13 - 14, Krefeld
2015	Health Council of the Netherlands Gezondheidsraad (GR)	4,4'-Methylenedianiline - Health-based calculated occupational cancer risk values
2006	HAYES, Inc.	3F8 monoclonal antibody therapy for the treatment of pediatric neuroblastoma
2020	Australian Safety and Efficacy Register of New Interventional Procedures -Surgical (ASERNIP-S)	3D printing applications in healthcare
2022	Agency for Care Effectiveness (ACE)	3D printing and its clinical applications
2022	National Institute for Health and Care Excellence (NICE)	3C Patch for treating diabetic foot ulcers. NICE medical technologies guidance 66
2009	HAYES, Inc.	3.0 Tesla (3T) Magnetic Resonance Imaging (MRI) for Prostate Cancer
2007	HAYES, Inc.	3.0 Tesla (3T) Magnetic Resonance Imaging (MRI) for multiple sclerosis
2004	Comite d'Evaluation et de Diffusion des Innovations Technologiques (CEDIT)	3 Tesla MRI - preliminary report
2003	Canadian Coordinating Office for Health Technology Assessment (CCOHTA)	24-hour ambulatory blood pressure monitoring
2015	Institute for Clinical Effectiveness and Health Policy (IECS)	23g and 25g vitrectomy for eye conditions
2015	Health Council of the Netherlands Gezondheidsraad (GR)	2,6-Xylidine - re-evaluation of the carcinogenicity and genotoxicity
2000	German Agency for Health Technology Assessment at the German Institute for Medical Documentation and Information (DAHTA DIMDI)	1st Symposium Health Technology Assessment - Current state and perspectives in German speaking countries, 2000, May 3 - 4, Cologne
1997	Health Council of the Netherlands Gezondheidsraad (GR)	1996 reports of the Health Council of the Netherlands (executive summaries)
2023	Health Information and Quality Authority (HIQA)	18F-PSMA PET/CT in the staging of primary prostate cancer and the restaging of recurrent prostate cancer: evidence synthesis to support a generic justification decision
2018	Andalusian Health Technology Assessment Area (AETSA)	18F-FDG PET in early diagnosis of degenerative diseases of the central nervous system
2006	Secretaria de Ciencia, Tecnologia e Insumos Estrategicos, Departamento de Ciencia e Tecnologia (DECIT-CGATS )	18-FDG positron emission tomography for non-small cell lung cancer: cost-effectiveness reports
2005	Secretaria de Ciencia, Tecnologia e Insumos Estrategicos, Departamento de Ciencia e Tecnologia (DECIT-CGATS )	18-FDG positron emission tomography for non-small cell lung cancer
2005	Secretaria de Ciencia, Tecnologia e Insumos Estrategicos, Departamento de Ciencia e Tecnologia (DECIT-CGATS )	18-FDG positron emission tomography for melanoma
2018	Norwegian Institute of Public Health (NIPH)	177Lutetium-based peptide receptor radionuclide therapy for treating neuroendocrine tumours: a health technology assessment
2024	Health Information and Quality Authority (HIQA)	¹⁷⁷Lutetium PSMA radioligand therapy for the treatment of metastatic castrate-resistant prostate cancer: Evidence synthesis to support a generic justification decision
2023	Norwegian Institute of Public Health (NIPH)	177Lu-PSMA-617 for treatment of metastatic castration resistant prostate cancer: a health technology assessment
2019	Ludwig Boltzmann Institut fuer Health Technology Assessment (LBI-HTA)	177Lu-PSMA Therapy in Patients with Metastatic Castration-Resistant Prostate
2023	Austrian Institute for Health Technology Assessment (AIHTA)	177Lu-PSMA radioligand therapy in patients with metastatic castration-resistant prostate cancer: Update 2023 - systematic review
2002	NIHR Horizon Scanning Centre (NIHR HSC)	131-iodine tositumomab for non-Hodgkin's lymphoma - horizon scanning review
2006	Institute for Clinical Effectiveness and Health Policy (IECS)	13-cis-retinoic acid (isotretinoin) for the treatment of glioblastoma multiforme
2025	National Institute for Health and Care Excellence (NICE)	12 SQ-HDM SLIT for treating allergic rhinitis and allergic asthma caused by house dust mites. NICE technology appraisal guidance 1045
2020	The National Health Care Institute (ZIN, Zorginstituut Nederland)	12 SQ-HDM SLIT (Itulazax®) for the treatment of allergic rhinitis or conjunctivitis induced by pollen from the birch homologous group
2020	Ontario Health	10-kHz high-frequency spinal cord stimulation for adults with chronic noncancer pain: a health technology assessment
2015	Health Council of the Netherlands Gezondheidsraad (GR)	1,4-Dioxane - re-evaluation of the carcinogenicity and genotoxicity
2009	Adelaide Health Technology Assessment (AHTA)	0.2-0.5 Tesla MRi for the detection of arthritis and musculoskeletal disease
2021	Austrian Institute for Health Technology Assessment (AIHTA)	≥ 12 month follow-up of patients with spinal muscular atrophy (SMA) treated with Spinraza®, Zolgensma® or combination therapies
2013	Ludwig Boltzmann Institut fuer Health Technology Assessment (LBI-HTA)	[Zostavax for the prevention of herpes zoster and postherpetic neuralagia. Pilot assessment using the draft HTA core model for rapid relative effectiveness assessment. Pilot-ID: WP-SA-1]
2025	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Zolbetuximab (gastric or gastro-oesophageal junction adenocarcinoma, HER2-negative) – Assessment in accordance with § 35a Social Code Book (SGB) V (1), Sentence 11]
2024	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Zilucoplan (generalized myasthenia gravis) – Benefit assessment according to §35a Social Code Book V]
2022	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Zanubrutinib (Waldenstroem macroglobulinaemia) - Benefit assessment according to §35a Social Code Book V]
2023	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Zanubrutinib (marginal zone lymphoma) - Benefit assessment according to §35a Social Code Book V]